BCTX
BriaCell Therapeutics Corp.
Biotechnology
Market Cap$5M
5Y Perf.-13.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BCTX vs ADCT vs RCUS vs NKTR
Revenue, margins, valuation, and 5-year total return — side by side.
ADCT
ADC Therapeutics S.A.
Biotechnology
Market Cap$445M
5Y Perf.-90.5%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-19.1%
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.66B
5Y Perf.-74.8%
BCTX vs ADCT vs RCUS vs NKTR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCTX | ADCT | RCUS | NKTR |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5M | $445M | $2.55B | $1.66B |
| Revenue (TTM) | $0.00 | $79M | $236M | $56M |
| Net Income (TTM) | $-38M | $-137M | $-369M | $-158M |
| Gross Margin | — | 90.7% | 90.7% | 80.1% |
| Operating Margin | — | -149.6% | -168.6% | -226.3% |
| Total Debt | $0.00 | $439M | $99M | $149M |
| Cash & Equiv. | $14M | $261M | $222M | $15M |
BCTX vs ADCT vs RCUS vs NKTR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCTX
ADCT
RCUS
NKTR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BriaCell Therapeuti… (BCTX) | 100 | 86.7 | -13.3% |
| ADC Therapeutics S.… (ADCT) | 100 | 9.5 | -90.5% |
| Arcus Biosciences, … (RCUS) | 100 | 80.9 | -19.1% |
| Nektar Therapeutics (NKTR) | 100 | 25.2 | -74.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCTX vs ADCT vs RCUS vs NKTR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BCTX leads in 2 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. ADC Therapeutics S.A. is the stronger pick specifically for growth and revenue expansion. RCUS and NKTR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BCTX
BriaCell Therapeutics Corp.
The Income Pick
BCTX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.56
- Lower volatility, beta 1.56, current ratio 5.01x
- Beta 1.56, current ratio 5.01x
- 0.4% margin vs NKTR's -284.2%
Best for: income & stability and sleep-well-at-night
ADCT
ADC Therapeutics S.A.
The Growth Play
ADCT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 14.9%, EPS growth 30.9%, 3Y rev CAGR -27.1%
- 14.9% revenue growth vs BCTX's -136.6%
Best for: growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS is the clearest fit if your priority is long-term compounding.
- 49.2% 10Y total return vs NKTR's -59.8%
- -35.3% ROA vs BCTX's -153.6%, ROIC -64.1% vs -12.6%
Best for: long-term compounding
NKTR
Nektar Therapeutics
The Momentum Pick
NKTR is the clearest fit if your priority is momentum.
- +7.8% vs BCTX's -86.8%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ADCT | 14.9% revenue growth vs BCTX's -136.6% |
| Quality / Margins | BCTX | 0.4% margin vs NKTR's -284.2% |
| Stability / Safety | BCTX | Beta 1.56 vs ADCT's 1.84 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | NKTR | +7.8% vs BCTX's -86.8% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs BCTX's -153.6%, ROIC -64.1% vs -12.6% |
BCTX vs ADCT vs RCUS vs NKTR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2025
BCTX vs ADCT vs RCUS vs NKTR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLADCTLAGGINGBCTX
Who Leads Where
ADCT leads in 1 of 6 categories
RCUS leads 1 • NKTR leads 1 • BCTX leads 0 • 2 tied
Explore the data ↓BCTXBriaCell Therapeutics…
0leads
NKTRNektar Therapeutics
1leads
RCUSArcus Biosciences, In…
1leads
ADCTADC Therapeutics S.A.
1leads
6 Total Categories
CATEGORYLEADERvs RCUSvs NKTRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ADCT3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RCUS5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ADCT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RCUS and BCTX operate at a comparable scale, with $236M and $0 in trailing revenue. Profitability is closely matched — net margins range from -156.4% (RCUS) to -2.8% (NKTR). On growth, NKTR holds the edge at +3.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $79M | $236M | $56M |
| EBITDAEarnings before interest/tax | -$43M | -$117M | -$391M | -$125M |
| Net IncomeAfter-tax profit | -$38M | -$137M | -$369M | -$158M |
| Free Cash FlowCash after capex | -$37M | -$115M | -$489M | -$160M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% | +90.7% | +80.1% |
| Operating MarginEBIT ÷ Revenue | — | -149.6% | -168.6% | -2.3% |
| Net MarginNet income ÷ Revenue | — | -173.0% | -156.4% | -2.8% |
| FCF MarginFCF ÷ Revenue | — | -144.7% | -2.1% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -9.5% | -39.3% | +3.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +92.3% | +41.7% | +10.5% | +49.7% |
ADCT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — BCTX and ADCT and NKTR each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $5M | $445M | $2.6B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | -$9M | $623M | $2.4B | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -3.13x | -7.71x | -8.42x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.47x | 10.34x | 30.09x |
| Price / BookPrice ÷ Book value/share | 0.33x | — | 4.32x | 15.38x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — BCTX and ADCT and NKTR each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
RCUS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
RCUS delivers a -69.0% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-194 for BCTX. RCUS carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTR's 1.66x. On the Piotroski fundamental quality scale (0–9), ADCT scores 4/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -193.8% | — | -69.0% | -87.0% |
| ROA (TTM)Return on assets | -153.6% | -44.7% | -35.3% | -40.7% |
| ROICReturn on invested capital | -12.6% | — | -64.1% | -57.2% |
| ROCEReturn on capital employed | -3.4% | -43.8% | -42.1% | -55.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 0 | 2 |
| Debt / EquityFinancial leverage | — | — | 0.16x | 1.66x |
| Net DebtTotal debt minus cash | -$14M | $178M | -$123M | $134M |
| Cash & Equiv.Liquid assets | $14M | $261M | $222M | $15M |
| Total DebtShort + long-term debt | $0 | $439M | $99M | $149M |
| Interest CoverageEBIT ÷ Interest expense | -796.67x | -1.72x | -13.38x | -6.23x |
RCUS leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,787 today (with dividends reinvested), compared to $88 for BCTX. Over the past 12 months, NKTR leads with a +782.4% total return vs BCTX's -86.8%. The 3-year compound annual growth rate (CAGR) favors NKTR at 92.1% vs BCTX's -84.3% — a key indicator of consistent wealth creation.
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -41.6% | -0.6% | +8.9% | +88.6% |
| 1-Year ReturnPast 12 months | -86.8% | +173.4% | +197.3% | +782.4% |
| 3-Year ReturnCumulative with dividends | -99.6% | +65.1% | +27.8% | +609.0% |
| 5-Year ReturnCumulative with dividends | -99.1% | -84.4% | -12.1% | -72.3% |
| 10-Year ReturnCumulative with dividends | — | -88.2% | +49.2% | -59.8% |
| CAGR (3Y)Annualised 3-year return | -84.3% | +18.2% | +8.5% | +92.1% |
NKTR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BCTX and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCTX is the less volatile stock with a 1.56 beta — it tends to amplify market swings less than ADCT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 88.3% from its 52-week high vs BCTX's 11.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.84x | 1.84x | 1.80x |
| 52-Week HighHighest price in past year | $37.20 | $4.97 | $28.72 | $109.00 |
| 52-Week LowLowest price in past year | $3.60 | $1.23 | $7.72 | $7.99 |
| % of 52W HighCurrent price vs 52-week peak | +11.3% | +70.4% | +88.3% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 44.1 | 52.9 | 50.5 |
| Avg Volume (50D)Average daily shares traded | 183K | 967K | 1.2M | 977K |
Evenly matched — BCTX and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ADCT as "Buy", RCUS as "Buy", NKTR as "Buy". Consensus price targets imply 114.3% upside for ADCT (target: $8) vs 18.3% for RCUS (target: $30).
| Metric | BCTXBriaCell Therapeu… | ADCTADC Therapeutics … | RCUSArcus Biosciences… | NKTRNektar Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $7.50 | $30.00 | $147.33 |
| # AnalystsCovering analysts | — | 12 | 18 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ADCT leads in 1 of 6 categories (Income & Cash Flow). RCUS leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallADC Therapeutics S.A. (ADCT)Leads 1 of 6 categories
Loading custom metrics...
BCTX vs ADCT vs RCUS vs NKTR: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is BCTX or ADCT or RCUS or NKTR a better buy right now?
For growth investors, ADC Therapeutics S.
A. (ADCT) is the stronger pick with 14. 9% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate ADC Therapeutics S. A. (ADCT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCTX or ADCT or RCUS or NKTR?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -12. 1%, compared to -99. 1% for BriaCell Therapeutics Corp. (BCTX). Over 10 years, the gap is even starker: RCUS returned +49. 2% versus ADCT's -88. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCTX or ADCT or RCUS or NKTR?
By beta (market sensitivity over 5 years), BriaCell Therapeutics Corp.
(BCTX) is the lower-risk stock at 1. 56β versus ADC Therapeutics S. A. 's 1. 84β — meaning ADCT is approximately 18% more volatile than BCTX relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.
04Which is growing faster — BCTX or ADCT or RCUS or NKTR?
By revenue growth (latest reported year), ADC Therapeutics S.
A. (ADCT) is pulling ahead at 14. 9% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -44. 5% for BriaCell Therapeutics Corp.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCTX or ADCT or RCUS or NKTR?
BriaCell Therapeutics Corp.
(BCTX) is the more profitable company, earning 0. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCTX leads at 0. 0% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BCTX or ADCT or RCUS or NKTR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BCTX or ADCT or RCUS or NKTR better for a retirement portfolio?
For long-horizon retirement investors, BriaCell Therapeutics Corp.
(BCTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BCTX and ADCT and RCUS and NKTR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.